Additionally, the DAPA-CKD trial (NCT03036150), though focusing on dapagliflozin, demonstrated class-level SGLT2 inhibitor efficacy in patients with chronic kidney disease (CKD) and albuminuria, a common CRS precursor. This evidence concerns the gene SLC5A2 and chronic kidney disease.